Investigator-Initiated Studies

CSL Behring is committed to saving lives and improving the quality of life for people with rare and serious diseases worldwide. This commitment is reflected in the support for investigator-initiated studies (IIS) that advance medical and scientific knowledge of CSL Behring products and the diseases they are designed to treat. CSL Behring also supports innovative clinical and basic science studies that address important medical and scientific questions related to our therapeutic areas of interest.

Areas of Focus

- Immunodeficiency
- Hemophilia Disorders
- Immune-mediated Neuromuscular Disorders
- Acquired & Oral Anticoagulant-Associated Bleeding
- Hereditary Angioedema (HAE)

Disclaimer: All materials submitted as IIS application must be non-confidential. By submitting an IIS application, you acknowledge that CSL Behring is under no obligation of confidentiality with respect to materials submitted.

Application Requirements

All applications to be submitted in English

A complete Investigator-Initiated Study application is to include the following:

An online application submitted through the portal
Signed and dated CV
Detailed study budget
Draft protocol

Application Request Process

Review "Areas of Focus" to identify if the grant request aligns with CSL Behring's areas of interest.
To start an application click on "Apply Here".
Log in to your account. First time requestors must create an account.
Your request will be reviewed and we will notify you via email of the decision.
If your request is approved, you will be contacted regarding the Agreement and disbursement process.

Frequently Asked Questions (FAQs)

Q: Who should I contact for more information regarding Investigator-Initiated Studies?
A: You can contact your regional Medical Science Liaison by clicking here.

Q: Should I submit a conceptual outline or a full study proposal?
A: You should submit a full proposal of the study for CSL Behring to consider for review. Conceptual or high-level proposals will not be considered until they are fully developed.

Q: How long does the review process take?
A: Full submissions are reviewed on a monthly basis and you will be notified when the CSL Behring Review Committee has arrived at a decision. Decisions are based on medical and scientific value in addition to current resources and research priorities.

Q: What is CSL Behring’s role in a funded Investigator-Initiated Study?
A: CSL Behring is considered the Grant Provider for any Investigator-Initiated Study that it funds. Due to certain legal implications, the role of Sponsor needs to be assumed by either the Investigator or the Investigator’s Organization.